全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...
-  2019 

Crossover safety study of aprepitant: 2-min injection vs 30-min infusion in cancer patients receiving emetogenic chemotherapy

DOI: 10.2147/OTT.S201609

Keywords: aprepitant, bag shortage, CINV, HTX-019, real world, short injection

Full-Text   Cite this paper   Add to My Lib

Abstract:

Introduction: HTX-019 (CINVANTI?) is a novel injectable emulsion formulation of the neurokinin 1 receptor antagonist (RA) aprepitant, approved for preventing acute and delayed chemotherapy-induced nausea and vomiting (CINV). HTX-019 has demonstrated a tolerable safety profile when administered via 30-min intravenous (IV) infusion and 2-min IV injection in healthy volunteers. This prospective study evaluated the safety of HTX-019 administered via 30-min IV infusion and 2-min injection (IV push) in patients with cancer

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133